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OBJECTIVES: Rituximab (MabThera®, RTX) is a novel geneti-
cally engineered anti-CD20 therapeutic monoclonal antibody for
rheumatoid arthritis (RA) patients in which anti-TNFa therapies
failed. The aim of this study is to assess the cost-effectiveness of
RTX relative to current therapy for RA patients not responding
adequately to anti-TNFa therapies. METHODS: Decision-
analytic model employing a Monte Carlo micro-simulation of a
Markov process with cohorts of 10,000 RA patients who had
responded inadequately to one anti-TNF therapy. The model
estimates lifetime HAQ progression, QALYs and direct costs
based on ACR response rates for sequences of treatments, avail-
able epidemiological data from observational studies and base-
line characteristics from both the REFLEX phase III trial and
VACAR study. This observational trial with 244 RA patients
in Spain yield functions converting HAQ scores into
utilities (HUI3 = 0.9527 - 0.2018*HAQ and EQ-5D = 0.9567 -
0.309*HAQ). Economic outcomes included costs (2008 €) for
therapy (comprising of: drug costs, administration and monitor-
ing), and those related to disease progression, palliative care and
reduced productivity. Both costs and beneﬁts were discounted at
an annual rate of 3.5%. RESULTS: Annual average treatment
costs were €7,469 for RTX+MTX, €13,954 for adalimumab,
€12,968 for etanercept, and €9,811 for inﬂiximab. Added to
existing therapies, RTX would lead to a gain of 0.523–0.781
QALYs (when baseline characteristics from REFLEX study,
0.619–0.908 for VACAR population) with an estimated ICER of
€13,593–21,703 per QALY gained (€11,143–17,899). CON-
CLUSIONS: Availability of RTX for Spanish RA patients who
respond inadequately to anti-TNF therapy results in a favourable
incremental cost per QALY gained. When RTX is replacing
another biologic DMARD, the average annual drug therapy costs
diminish. If utility functions from VACAR study are used with
REFLEX population, QoL results are robust when compared to
common utility functions in RA literature (Bansback et al 2004,
Hurst et al 1997, Kobelt et al 1999).
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OBJECTIVES: Using a model constructed to predict resource
consumption and health outcomes in a population-based regis-
try of biological treatments in Southern Sweden (SSATG) to
estimate the cost-effectiveness of rituximab, a monoclonal anti-
body recently approved for the treatment of active rheumatoid
arthritis (RA) in patients not responding adequately to TNF-
inhibitor treatment. METHODS: The model was developed as a
Discrete Event Simulation model, using SSATG data for the
years 1999–2007. The dataset included 1903 patients with com-
plete data on treatments (up to 3 treatment lines), functional
capacity (HAQ), disease activity (DAS28) and utility (EQ-5D).
Resource consumption is based on a regular population-based
survey of patients in the area of Malmö (Southern Sweden).
Rituximab was incorporated as second-line treatment, using
effectiveness data for the active group (N = 311) from a clinical
trial comparing rituximab to placebo (REFLEX). It is thus com-
pared to the mix of second line biologics used in SSATG. The
analysis starts after failure of the ﬁrst TNF-inhibitor. Results are
reported as costs (€2008) per QALY (both discounted 3%),
for the societal perspective in Sweden. RESULTS: The model
predicted 2.6 treatment courses in the rituximab arm and 2.4
treatment courses in the TNF-inhibitor arm. Total costs in the
rituximab strategy are estimated at €403,400 compared to
€406,000 in the TNF-inhibitor arm. Total QALYs are 5.98 and
5.78 respectively. Rituximab is thus the dominant strategy, with
savings of €2600 and a QALY gain of 0.20. The ﬁndings were
found to be robust in extensive sensitivity analysis. CONCLU-
SIONS: In our model, a strategy where rituximab is used as
second line treatment after failure of the ﬁrst TNF-inhibitor
provides a small saving (essentially due to the lower price of
rituximab) and a QALY gain (due to better effect than the mix
of second line TNF-inhibitors).
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OBJECTIVES: To estimate the cost–utility of abatacept in
patients with moderately to severely active Rheumatoid Arthritis
(AR) and an insufﬁcient response or intolerance to anti-tumor
necrosis factor (TNF) therapies, in the Italian setting.
METHODS: A probabilistic patient level simulation model was
developed to estimate long-term costs and health outcomes of
abatacept versus anti-TNF therapies (etanercept, adalimumab,
inﬂiximab) in RA patients. The model predicted patients’ Health
Assessment Questionnaire (HAQ) scores over time based on the
initial response to treatment (% change in HAQ score at six
months). Responding patients continued treatment with a
reduced rate of HAQ progression until long-term treatment
failure. Health-state utilities and use of health care resources
(excluding RA therapies) were assumed to depend on HAQ
scores. The model used data from a Phase III clinical trial of
abatacept in patients with inadequate response to anti-TNFs
(Abatacept Trial in Treatment of Anti-TNF Inadequate respond-
ers) and various secondary data sources. The National Health
Service perspective was used. Cost–utility of abatacept vs anti-
TNF therapies was derived in terms of incremental cost per
quality-adjusted life-year (QALY), based on a 20 years time
horizon, with costs expressed in Euros. Single-way sensitivity
analyses and cost-effectiveness acceptability-curve were per-
formed. Costs and health effects were discounted at 3% annually.
RESULTS: Abatacept vs anti-TNF therapies was estimated to
yield 0.66 additional QALYs per patient at an incremental cost of
€10,096.40, based on a 20 years time horizon. Cost per QALY
gained was €15,278.20. These results were robust to variation of
key model parameters. The acceptability-curve showed that
Abatacept has a likelihood of 100% to be cost-effective in com-
parison to anti-TNFs with at willingness-to-pay threshold of
€30,000.00. CONCLUSIONS: This study shows that in Italy,
compared to anti-TNF therapies, Abatacept is cost-effective in
patients with moderately to severely active RA, with an insufﬁ-
cient response or intolerance to anti-TNF therapy.
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